Chengalroyan Raghunathan
Interventional Cardiology · Paramount, CANPI 1407904089
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 373 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,702 and has fallen 58.9% since, to $1,111 in 2022. That places this record below the midpoint for interventional cardiology clinicians in CA, where the typical reported total is $8,581.
Across 373 payments — averaging $21.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Boehringer Ingelheim$1K
- Johnson & Johnson$926
- GSK$918
- Novartis$522
- plus $2K from 15 others
What the payments were for
- Food & beverage$7,927100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 50 | $1,296 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 49 | $1,141 |
| Boehringer Ingelheim | 60 | $1,057 |
| Johnson & Johnson | 44 | $926 |
| GSK | 35 | $918 |
| Novartis | 51 | $522 |
| Amarin Pharma, Inc. | 19 | $512 |
| Bayer | 8 | $440 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $258 |
| Merck | 12 | $220 |
| Pfizer | 7 | $206 |
| E.r. Squibb & Sons, L.L.C. | 7 | $164 |
| Amgen | 4 | $81 |
| Novo Nordisk | 2 | $41 |
| AbbVie | 2 | $38 |
| Gilead | 1 | $30 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Circassia Inc. | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,943 in reported general payments places this provider in the 45th percentile of 585 interventional cardiology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Famotidine | 13 | $369 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Paramount
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
- Evan ZahnLos Angeles$632K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.